A method of preserving a donor organ for transplantation may include flushing the donor organ with flush solution comprising itaconate and storing the flushed donor organ. The flush solution may comprise dimethyl itaconate (DI) in an amount greater than or equal to 0.1 mM and less than or equal to 0.75 mM. Following removal from storage, the donor organ may be perfused using an ex vivo organ perfusion (EVOP) process. The perfusate may also include itaconate.

Described herein is a method of preserving a biological tissue sample ex vivo, the method comprising comprises contacting the tissue sample ex vivo with a perfusion solution comprising polymerized hemoglobin, wherein the perfusion solution comprises less than 5% by weight low molecular weight hemoglobin species, based on the total weight of the perfusion solution.

The present invention is a formulation for oxygen delivery for organ preservation comprising a scalable stabilized nanoemulsion, and a method for using it. The nanoemulsion embraces a hydrocarbon lipid; a fluorocarbon or perfluorocarbon; water; a nonionic surfactant; and optionally a quaternary ammonium compound, so that droplets of the nanoemulsion have a droplet size of from about 90 nm to about 120 nm and wherein the diameter of the droplets does not change by more than 20% upon storage for at least 12 months.

The present invention is a formulation for oxygen delivery for organ preservation comprising a scalable stabilized nanoemulsion, and a method for using it. The nanoemulsion embraces a hydrocarbon lipid; a fluorocarbon or perfluorocarbon; water; a nonionic surfactant; and optionally a quaternary ammonium compound, so that droplets of the nanoemulsion have a droplet size of from about 90 nm to about 120 nm and wherein the diameter of the droplets does not change by more than 20% upon storage for at least 12 months.

A composition and method of use thereof wherein the composition comprises one or more components capable of releasing an aldehyde, one or more anticoagulants or chelating agents, and one or more polysaccharides. The composition has a pH of from about 4 to about 6.

A composition and method of use thereof wherein the composition comprises one or more components capable of releasing an aldehyde, one or more anticoagulants or chelating agents, and one or more polysaccharides. The composition has a pH of from about 4 to about 6.

Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) cryoprotectant: the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol, and ethylene glycol; (3) a saline buffer; wherein the salt buffer is a solution containing Na.sup.+, K.sup.+, Mg.sup.+, Cl.sup., and CH.sub.3COO.sup. ions; (4) a vitamin; and (5) an amino acid, wherein the human albumin concentration is 1%-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used or conventional adherent and suspension cells.

Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) cryoprotectant: the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol, and ethylene glycol; (3) a saline buffer; wherein the salt buffer is a solution containing Na.sup.+, K.sup.+, Mg.sup.+, Cl.sup., and CH.sub.3COO.sup. ions; (4) a vitamin; and (5) an amino acid, wherein the human albumin concentration is 1%-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used or conventional adherent and suspension cells.

The present invention provides methods and compositions for decontamination and preservation osteochondral tissue, such as an osteoarticular fracture fragment, meniscus, meniscal tissue, cartilage or other component of a joint or bone tissue fragment autograft, for extended periods of time at room temperature in a tissue storage container or bag. The invention further provides a process for maintaining the sterility of the osteochondral tissue using the apparatus as described.

The present invention provides methods and compositions for decontamination and preservation osteochondral tissue, such as an osteoarticular fracture fragment, meniscus, meniscal tissue, cartilage or other component of a joint or bone tissue fragment autograft, for extended periods of time at room temperature in a tissue storage container or bag. The invention further provides a process for maintaining the sterility of the osteochondral tissue using the apparatus as described.